Free Trial

Invesco Ltd. Grows Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX

Catalyst Pharmaceuticals logo with Medical background

Key Points

  • Invesco Ltd. raised its stake in Catalyst Pharmaceuticals by 41.7%, owning 1,199,627 shares valued at approximately $29.09 million.
  • Currently, 79.22% of Catalyst Pharmaceuticals' stock is held by institutional investors, reflecting strong institutional interest.
  • Wall Street analysts have given Catalyst Pharmaceuticals a consensus rating of "Buy" and a price target of $33.20, indicating positive future growth expectations.
  • Want stock alerts on Catalyst Pharmaceuticals? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Invesco Ltd. lifted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 41.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,199,627 shares of the biopharmaceutical company's stock after purchasing an additional 352,776 shares during the quarter. Invesco Ltd. owned about 0.98% of Catalyst Pharmaceuticals worth $29,091,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CPRX. Park Square Financial Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $29,000. Sound Income Strategies LLC purchased a new position in Catalyst Pharmaceuticals in the first quarter worth approximately $64,000. GAMMA Investing LLC grew its position in Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after acquiring an additional 579 shares during the period. Quarry LP purchased a new position in Catalyst Pharmaceuticals in the fourth quarter worth approximately $104,000. Finally, New Vernon Capital Holdings II LLC purchased a new position in Catalyst Pharmaceuticals in the fourth quarter worth approximately $122,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 2,324 shares of the stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total transaction of $61,376.84. Following the transaction, the insider owned 42,681 shares of the company's stock, valued at approximately $1,127,205.21. This represents a 5.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Trading Up 2.5%

CPRX traded up $0.52 during mid-day trading on Friday, hitting $21.08. 1,110,487 shares of the stock were exchanged, compared to its average volume of 1,440,265. The firm's fifty day moving average is $21.29 and its two-hundred day moving average is $22.60. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.00 and a 1-year high of $26.58. The company has a market cap of $2.58 billion, a PE ratio of 12.78, a PEG ratio of 0.86 and a beta of 0.70.

Analysts Set New Price Targets

Several brokerages recently weighed in on CPRX. Wall Street Zen lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Finally, Zacks Research lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $33.20.

Check Out Our Latest Stock Analysis on Catalyst Pharmaceuticals

About Catalyst Pharmaceuticals

(Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Recommended Stories

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Should You Invest $1,000 in Catalyst Pharmaceuticals Right Now?

Before you consider Catalyst Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.

While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines